郭展維醫生 - 內科腫瘤科
內科腫瘤科專科醫生
重點資料
- 醫務委員會註冊已驗證
- 內科腫瘤科專科醫生香港大學內外全科醫學士 · 香港內科醫學院院士 · 2010 年醫科畢業
- 保險計劃資料整理中｜查看詳情
關於醫生
郭展維醫生是香港註冊的內科腫瘤科專科醫生。
學歷
保險計劃
常見問題
郭展維醫生好嗎？
郭展維醫生是香港註冊的內科腫瘤科專科醫生。資歷及註冊資料來自香港醫務委員會。ok.med 不評分，也不排名。
郭展維醫生是做什麼的？
郭展維醫生是內科腫瘤科醫生。
研究及論文
共 7 篇
按論文主題篩選
主題由同一批 PubMed 論文的醫學分類整理，不代表醫生提供相關診治服務。
- High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis.Thyroid : official journal of the American Thyroid Association · 2025
- Role of Circulating Tumor DNA Tumor Fraction in Advanced Non-Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study.JCO precision oncology · 2025
- Response to Kakudo et al.: "High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis".Thyroid : official journal of the American Thyroid Association · 2025
- A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.Investigational new drugs · 2025
- Fulminant tumour lysis syndrome after nivolumab and ipilimumab treatment for hepatocellular carcinoma.Journal of hepatology · 2025
- Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.Postgraduate medical journal · 2022
- Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.Postgraduate medical journal · 2019
論文資料來自 PubMed／Europe PMC，按姓名及機構自動配對；每項均可按連結核對。
僅供參考，不構成醫療建議。 閱讀完整免責聲明